U.S., May 17 -- ClinicalTrials.gov registry received information related to the study (NCT06974799) titled 'Metabolomic Biomarkers Evaluation in Pulmonary Fibrosis' on April 25.
Brief Summary: Pulmonary fibrosis (PF) are a heterogeneous group of interstitial lung diseases who may have a progressive phenotype often associated with loss of lung function, chronic respiratory symptoms, quality of life limitation as well significant morbidity and mortality. The identification of reliable biomarkers able to help in early diagnosis and predict disease progression are crucial for improving patient life. Although many biomarkers have been proposed, there is no consensus on reliable markers for IPF. Alterations in fatty acid (FA) metabolism have dra...